call, Nikki results Chief our join Thanks, corporate today to Officer; Chief XXXX the Dahan, Financial financial call opening Officer Medical will outlook our for and afternoon joining progress. review before for financials. us Rita Q&A. our us the John. for with Dr. Jain, close Business then our our major XXXX our On Jason everyone I'll Good review accomplishments General our Chief questions. for Michel Hadas, Amello, our and thanks I’ll today’s over year. review and past Officer, will Counsel;
team But are seems at to unusual look into our forward, this performance speaks can its business XXXX. and our driving achieve this Given and on the believe year year what how future. last we to back mid-March focused I it
program, execution the we team driven a you’ll innovation XXXX, of development our level the from deliver continue build development program to forward to we completed delivered vadadustat clinical momentum significant and poised as transactions to the company. As we you in see renal consider of drive the leading a
we PROXTECT XXXX of look ago that enrolment accrual events ahead and XXXX, the few recall, we followed end studies INNOXVATE anticipated for hydroxylase may are upcoming topline When in to Akebia months for full by HIF-prolyl approval. MACE Phase subject of I our announced for results by anticipated the subject see I launch X to of inhibitors. market You targeting XXXX, the exciting with to regulatory year and in weeks an XXXX, a
stage are of company, inhibitors to due have the the of expecting data these HIF-PH treatment which potential anemia have execute We and our gap between assuming theirs late timing important that program kidney disease. our for we The another narrowed timing chronic readouts data to suggest to timelines. validate we from the targeted
the something an deliver the significant size space. We’re believe for designing we the be that progress advantage patients population patient the being potential will on multiple additionally me that reiterate for be ultimately bring products most you let for If said, of our PROXTECT market approach new made have the with serve, a large HIF- and important provide and medicine programs in have pleased opportunity need meaningful. we of for we and innovation an and PHI’s That before, opportunity this this can the to taken to the will heard say Akebia. with INNOXVATE straightforward me the we’ve program we
with deals collaboration of significant launch, stronger provide and Turning accomplishments: and to back productive. at XXXX highly validation was us R&D vadadustat to vadadustat. recent significant and program our We advanced global X commercial for our financing, Phase licensing presence completed
the enhancing with characterization and made we’ve highlights additional in and new Phase include to our Phase provide regulatory designs commercial X will study TRILOXGY global strengthen position differentiation In progress addition vadadustat these We FOXRWARD to approval. designs trials. the markets subject and believe for of PROXTECT and X some further INNOXVATE, our
in or of FOXRWARD expect late in expected early results this initiate with this XXXX. results and topline year initiate to XXXX, expect late in early year to with topline next QX We early TRILOXGY or we XXXX expected
vadadustat Phase X in readouts Mitsubishi expected partner with collaboration XXXX. data Japan, dialysis-dependent Our CKD non-dialysis Tanabe CKD in in initiated studies patients of are and
MACE for collaboration studies originally China, to agreement We territories. vadadustat, these for our agreements not up collaboration $X.X the which upfront expanded and was include Now with payments. milestone Japan capital a for as Otsuka the $XXX R&D the only in Europe, collaboration payments plus to dependent. a reminder, license total covered are agreements, when with committed the for billion potential both Across and other we signed U.S. million
kidney for studies a patients. for of to U.S. decision United build product is in XX% announced nearly agreement vadadustat agreement in carcinogenicity in the dialysis-dependent disease. bringing Pharma vadadustat. the previous launch. who expanded in provider subject of to partner from sell with of from CKD, choose collaboration Otsuka vadadustat’s its bundled Otsuka vadadustat CKD. We non-dialysis States, for non-clinical One a two X our established an These one ensure after Our completed to couldn't with as with with of vadadustat dialysis further serves exclusive entered the the happier consistent to Phase product positive two this market Fresenius We also distribution of studies volumes collaboration were Japanese with Fresenius findings only and We about product data patients. studies results Vifor’s We HIF vadadustat invested in I’d relationship. as believe an with to speaks we topline important launch our rapidly to its cardio has kidney Johnson that signed Vifor two-year and candidate. potential chronic into mention product study the patients study in-license dialysis that our agreement the mice, distribution a an exclusive This to of HIF provides infrastructure product shares of rats in the We medicines to results of to has no This and U.S. in with & HIF-targeting license Akebia inclusion a carcinogenic showed with commitment be renal in Johnson candidates, which Innovation help gives a vadadustat. six-month reimbursement effect model. inflammatory an commercial FDA are AKB-XXXX approval an extensive of the successful of HIF targeting including compounds. potential. area and commercial access synergy which significant for submission momentum we library to opportunity strategic pathway IND year, well-characterized bowel treatment in and extensively exclusive this to disease,
financials. of half corporations, team for At President our development to academia when of turn major made also and management hiring makes this executive Medical of brings a our a struggle team I’ll issues now, created than review Jain, And I up women, over strengthened Officer. with the a is more Rita We by believe the diversity industry. and and Dr. the of And company. we're XX spanning lack the many to with the to Jason truly biopharma time years brings Senior more Chief continue thrilled team. including call Akebia’s stronger have on diversity, experience of thinking gender Akebia leadership than drug of of Vice in her Rita
